Compare CAVA & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAVA | AXSM |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 11.2B |
| IPO Year | 2023 | 2015 |
| Metric | CAVA | AXSM |
|---|---|---|
| Price | $66.58 | $206.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 17 |
| Target Price | $91.00 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 3.2M | 643.5K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $1,179,664,000.00 | N/A |
| Revenue This Year | $25.71 | $57.24 |
| Revenue Next Year | $20.57 | $55.88 |
| P/E Ratio | $173.77 | ★ N/A |
| Revenue Growth | ★ 22.41 | N/A |
| 52 Week Low | $43.41 | $112.90 |
| 52 Week High | $98.79 | $260.19 |
| Indicator | CAVA | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | N/A |
| Support Level | $60.12 | N/A |
| Resistance Level | $68.88 | N/A |
| Average True Range (ATR) | 2.84 | 0.00 |
| MACD | 0.20 | 0.00 |
| Stochastic Oscillator | 45.85 | 0.00 |
Cava Group Inc owns and operates a chain of restaurants. It operates a Mediterranean-inspired fast-casual restaurant brand offering menu items. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: i) CAVA: It includes the operations of all company-owned CAVA restaurants, and ii) CAVA Foods: It includes the production of dips, spreads, and certain dressing bases used in CAVA restaurants as well as sales from the Company's consumer packaged goods business. The company generates the majority of its revenue from the CAVA segment.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.